Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Open accessAbstract
Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes. Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Interventions: Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy. Main Outcomes and Measures: The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death. This outcome was analyzed by baseline diabetes status and, in patients without diabetes, by glycated hemoglobin level less than 5.7% vs greater than or equal to 5.7%. Results: Among 4744 patients randomized (mean age, 66 years; 1109 [23%] women; 2605 [55%] without diabetes), 4742 completed the trial. Among participants without diabetes, the primary outcome occurred in 171 of 1298 (13.2%) in the dapagliflozin group and 231 of 1307 (17.7%) in the placebo group (hazard ratio, 0.73 [95% CI, 0.60-0.88]). In patients with diabetes, the primary outcome occurred in 215 of 1075 (20.0%) in the dapagliflozin group and 271 of 1064 (25.5%) in the placebo group (hazard ratio, 0.75 [95% CI, 0.63-0.90]) (P value for interaction = .80). Among patients without diabetes and a glycated hemoglobin level less than 5.7%, the primary outcome occurred in 53 of 438 patients (12.1%) in the dapagliflozin group and 71 of 419 (16.9%) in the placebo group (hazard ratio, 0.67 [95% CI, 0.47-0.96]). In patients with a glycated hemoglobin of at least 5.7%, the primary outcome occurred in 118 of 860 patients (13.7%) in the dapagliflozin group and 160 of 888 (18.0%) in the placebo group (hazard ratio, 0.74 [95% CI, 0.59-0.94]) (P value for interaction = .72). Volume depletion was reported as an adverse event in 7.3% of patients in the dapagliflozin group and 6.1% in the placebo group among patients without diabetes and in 7.8% of patients in the dapagliflozin group and 7.8% in the placebo group among patients with diabetes. A kidney adverse event was reported in 4.8% of patients in the dapagliflozin group and 6.0% in the placebo group among patients without diabetes and in 8.5% of patients in the dapagliflozin group and 8.7% in the placebo group among patients with diabetes. Conclusions and Relevance: In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status. Trial Registration: ClinicalTrials.gov Identifier: NCT03036124.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The benefits of dapagliflozin on cardiovascular outcomes were consistent in patients with and without type 2 diabetes in DAPA-HF.
“We have reported that the benefits of dapagliflozin on cardiovascular outcomes were consistent in patients with and without type 2 diabetes in DAPA-HF.23”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140 · see citing works
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · see citing works
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,738 · see citing works
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827 · see citing works
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · see citing works
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999 · see citing works
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969 · see citing works
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907 · see citing works
Self-citation2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750 · see citing works
Self-citationInzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · see citing works
Self-citationSantos‐Gallego, C. G., Requena-Ibáñez, J. A., Antonio, R. S., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., García‐Ropero, Á., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 664 · see citing works
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634 · see citing works
Verma, S., Mazer, C. D., Yan, A. T.-K., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., FITCHETT, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 587 · see citing works
Self-citationHallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499 · see citing works
Self-citationMcMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1432 · Cited by 433 · see citing works
Self-citationNassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424 · see citing works
Self-citationThe actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 351 · see citing works
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A. A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.048 · Cited by 337 · see citing works
Self-citationYurista, S. R., Silljé, H. H. W., Oberdorf‐Maass, S. U., Schouten, E., Pávez, M., Hillebrands, J., van Goor, H., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1473 · Cited by 322 · see citing works
Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283 · see citing works
Chatterton, H. T., Younger, T., Fischer, A., Khunti, K. K., & on behalf of the Programme Development Group (2012) · BMJ · doi:10.1136/bmj.e4624 · Cited by 107 · see citing works
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 82 · see citing works
Self-citationGarg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82 · see citing works
Self-citationA win ratio approach to comparing continuous non‐normal outcomes in clinical trials
Wang, D., & Pocock, S. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1743 · Cited by 79 · see citing works
Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Wójcik, C., & Warden, B. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1219-4 · Cited by 61 · see citing works
Devineni, D., Vaccaro, N. M., Polidori, D., Rusch, S., & Wajs, E. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.02.022 · Cited by 48 · see citing works
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 42 · see citing works
Self-citationInhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
Pfister, M., Whaley, J. M., Zhang, L., & List, J. F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.16 · Cited by 31 · see citing works
Yanai, H., & Katsuyayama, H. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2857w · Cited by 21 · see citing works
Dewan, P., Jhund, P. S., Shen, L., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.2019.21.issue-5 · Cited by 11 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598 · see citing works
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408 · see citing works
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020 · see citing works
Self-citationRao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625 · see citing works
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596 · see citing works
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556 · see citing works
Self-citationAnker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051824 · Cited by 352 · see citing works
Self-citationJhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307 · see citing works
Self-citationSpertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01703-8 · Cited by 245 · see citing works
Self-citationLiu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155 · see citing works
Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059785 · Cited by 131 · see citing works
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047480 · Cited by 95 · see citing works
Self-citationNeuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14226 · Cited by 78 · see citing works
Yang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79 · see citing works
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48 · see citing works
Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy
Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1402 · Cited by 44 · see citing works
Self-citationKhunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14805 · Cited by 37 · see citing works
Self-citationOdutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29 · see citing works
Self-citationGoldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23 · see citing works
Self-citation
- Authors
- Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., Howlett, J., Katova, T., Kitakaze, M., Ljungman, C. E. A., Merkely, B., Nicolau, J. C., O'Meara, E., Vinh, P. N., Schou, M., Tereshchenko, S., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Johanson, P., Greasley, P. J., Boulton, D., Bengtsson, O., Jhund, P. S., & McMurray, J. J. V.
- Affiliations
- University of Glasgow (GB)
- St. Michael's Hospital (CA)
- Yale University (US)
- University of Minnesota (US)
- Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
- Universitätsklinikum des Saarlandes (DE)
- Taipei Veterans General Hospital (TW)
- Department of Cardiology, Medanta, Gurgaon, Haryana, India
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- Brigham and Women's Hospital (US)
- Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
- Department Cardiology, Medical University of Lodz, Lodz, Poland
- Comenius University Bratislava (SK)
- Fudan University (CN)
- University of Calgary (CA)
- National Heart Hospital (BG)
- National Cerebral and Cardiovascular Center (JP)
- University of Gothenburg (SE)
- Semmelweis University (HU)
- Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
- Department of Cardiology, Montreal Heart Institute, Montreal, Ontario, Canada
- Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam
- Gentofte Hospital (DK)
- National Medical Research Center of Cardiology (RU)
- Copenhagen University Hospital (DK)
- University of Missouri–Kansas City (US)
- AstraZeneca (Sweden) (SE)
- Universidad Nacional de Córdoba, Córdoba, Argentina
- Wroclaw Medical University (PL)
- AstraZeneca (United States) (US)
- Corresponding author
- McMurray, John J. V.
- ORCID
- Petrie, Mark C.
- Verma, Subodh
- Docherty, Kieran F.
- Inzucchi, Silvio E.
- Anand, Inder
- Böhm, Michael
- Chiang, Chern-En
- Chopra, Vijay K.
- Desai, Akshay S.
- Ge, Junbo
- Howlett, Jonathan
- Kitakaze, Masafumi
- Ljungman, Charlotta E. A.
- Merkely, Béla
- Schou, Morten
- Tereshchenko, Sergey
- Køber, Lars
- Kosiborod, Mikhail N.
- Langkilde, Anna Maria
- Ponikowski, Piotr
- Sabatine, Marc S.
- Sjöstrand, Mikaela
- Solomon, Scott D.
- Johanson, Per
- Greasley, Peter J.
- Boulton, David
- Bengtsson, Olof
- Jhund, Pardeep S.
- McMurray, John J. V.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-04-14
- Volume
- 323
- Issue
- 14
- Pages
- 1353
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC7157181
- OpenAlex
- W3013838418
- Cited by
- 531
- References
- 32
- Citations by year
- 2026: 37 · 2025: 46 · 2024: 75 · 2023: 90 · 2022: 103 · 2021: 124 · 2020: 53
- FWCI
- 57.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca (RE/18/6/34217)
- GlaxoSmithKline
- Sanofi
- Brigham and Women's Hospital
- Gilead Sciences
- Alnylam Pharmaceuticals
- Celladon Corporation
- Ironwood Pharmaceuticals, Incorporated
- Intarcia Therapeutics
- Amarin Corporation
- Cytokinetics
- IFM Therapeutics
- MyoKardia
- Impulse Dynamics
- Zora Biosciences
- British Heart Foundation (18/6/34217, RE/18/6/34217)
- Kidney Research UK
- Daiichi-Sankyo
- Eisai
- Vifor Pharma
- Servier
- Esperion Therapeutics
- National Institutes of Health
- Sanofi Pasteur
- Respicardia
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK045735)
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, heart failure with reduced ejection fraction, SGLT2 inhibitors, worsening heart failure, cardiovascular mortality, diabetes mellitus, HbA1c, N-terminal pro-brain natriuretic peptide, ejection fraction, glycemic control, heart failure with preserved ejection fraction, subgroup analysis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Heart Failure, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Stroke Volume, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
